An observational study in Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Lung Neoplasms by Bristol-Myers Squibb — 6 open to participants now, 9 under way, 2 of them phase 3. Lung Neoplasms · Bristol-Myers Squibb.
Among the 40 studies in Lung Neoplasms by Bristol-Myers Squibb, this one is one of 7 that started in 2016, is one of 6 observational ones, and was the 24th registered.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →6 of the 40 studies in Lung Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Belgium, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 31 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, Spain
Ages 18+
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 22 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 14 · Phase 3 11 · Phase 4 2
First in 2003; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,462 is above the median of 200 across 1,435 observational studies indexed under Lung Neoplasms.
Median enrollment 220 across the 34 interventional studies, 977 across the 6 observational. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Lung Neoplasms by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France
This study aims to collect data for patients diagnosed with a lung cancer and initiating nivolumab in France
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the drugs
Other protocol defined inclusion or exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
Other: Non-Interventional
Non-Interventional
This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.
Distribution of gender
Time frame: At baseline
Distribution of age
Time frame: At baseline
Distribution of line of therapy at nivolumab initiation
Time frame: At baseline
Distribution of ECOG PS
Eastern Cooperative Oncology Group Performance Status (ECOG PS) A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis
Time frame: At baseline
Distribution of patients working status at nivolumab initiation
Time frame: At baseline
QoL (EQ-5D) at nivolumab initiation
Quality of Life (QoL) as assessed by European Quality of Life-5 Dimensions (EQ-5D) EQ-5D: the descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)
Time frame: At baseline
Median time from initial diagnosis to nivolumab initiation
Median time from initial diagnosis to nivolumab initiation (derived from date of initial diagnosis and date of first dose of nivolumab, assumed to be the date of D0 visit). Any lung cancer declaring more than 5 years after another cancer is defined as an initial diagnosis of lung cancer
Time frame: At baseline
Number of patients exposed to other lung cancer treatments
Time frame: At baseline
Distribution of current smokers, former smokers, and non-smokers at initial diagnosis
Time frame: At baseline
Distribution of cancer stage at initial diagnosis and at nivolumab initiation
Time frame: At baseline
Distribution of Lung cancer histology at initial diagnosis
Time frame: At baseline
Number of patients with untreated brain metastasis at nivolumab initiation
Time frame: At baseline
Number of patients with treated brain metastasis at nivolumab initiation
Time frame: At baseline
Number of patients with PD-L1 expression at nivolumab initiation
PD-LI (Programmed death-ligand 1)
Time frame: At baseline
Number of patients with mutations at nivolumab initiation
Time frame: At baseline
Distribution of concomitant diseases at nivolumab initiation
Time frame: At baseline
Number of patients with corticosteroids treatment at nivolumab initiation
Time frame: At baseline
(OS) Overall Survival
Time from index date (treatment with nivolumab) until date of death due to any cause
Time frame: Up to 3 years
Overall Survival after initiation of nivolumab
Time frame: Up to 2 years
Distribution of nivolumab adverse drug reaction
Time frame: At 3 years after nivolumab initiation
Progression Free Survival (PFS)
PFS measured by time since index date (initial treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first as assessed by RECIST 1.1
Time frame: Up to 3 years after nivolumab initiation
Objective Response Rate (ORR)
ORR is measured by the sum of partial responses plus complete responses as assessed by (RECIST 1.1) Response Evaluation Criteria In Solid Tumors
Time frame: Up to 3 years after nivolumab initiation
Quality of Life (QoL)
Time frame: Baseline to 3 years after nivolumab initiation
Distribution of patient management treatment patterns
Time frame: Baseline to 3 years
Mean weight change in kilogram from baseline
Time frame: Baseline up to 3 years
Mean ECOG PS change from baseline
Time frame: Baseline up to 3 years
Distribution of patients with new metastasis
Time frame: Up to 3 years
Distribution of patients with progression of pre-existing sites
Time frame: Up to 3 years
Ran from Oct 2016 to primary completion in Dec 2020, 50 months.
Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's 50 months is close to that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.